# OnCo record keynote-689 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-689/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-689", "NCT03765918" ;
  schema:name "KEYNOTE-689"@en ;
  schema:description "The first new treatment for curable head and neck cancer in six years: immunotherapy around surgery doubled the time patients stayed free of events."@en ;
  schema:url <https://onco.cc/trials/keynote-689/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03765918>, <https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-for-pd-l1-resectable-locally-advanced-head-neck-squamous-cell-carcinoma-as-neoadjuvant-treatment-continued-as-adjuvant-treatment-combined-with-radiother/> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2018-12-17" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/cps/> ;
  onco:people <https://onco.cc/people/ravindra-uppaluri/> .